Targeted therapies are being studied to advance treatment options for patients with actionable biomarkers

  • ALK, BRAF, EGFR, HER2, KIT, and ROS1 are biomarkers that have changed the course of therapy in multiple cancer types 11-13
  • However, many cancer types do not have well-established biomarkers. Investigational targets such as TRK could be relevant for some patients with cancer

Personalized medicine may help you take advantage of biomarkers such as TRK

  • It helps you see beyond the type of tumor to exactly which mutations are driving that tumor, allowing you to treat based on specific biomarkers 9
  • However not all patients are tested for actionable biomarkers, which prevents eligible patients from receiving targeted therapies 14
  • Genentech is committed to helping ensure that the benefits of personalized medicine reach as many patients as possible. Click here for more information
TRK cancer types

Molecular testing allows you to identify patients with TRK+ disease.

Double helix with people

ALK=anaplastic lymphoma kinase; BRAF=B-Raf proto-oncogene; serine/threonine kinase; EGFR=epidermal growth factor receptor; HER2=human epidermal growth factor receptor 2; KIT=KIT proto-oncogene receptor tyrosine kinase; MASC=mammary analogue secretory carcinoma; NGS=next generation sequencing; ROS1=ROS proto-oncogene 1; TRK=tropomyosin receptor kinase.